• Survival rates are comparable: median overall survival is 37.3 months with laparoscopic versus 34.1 months with open surgery.
• Postoperative complications are similar in both groups, but hospital stays are shorter for laparoscopic patients.
• Patient selection is crucial; extraperitoneal metastasis significantly impacts survival outcomes.

Consider laparoscopic cytoreductive surgery for suitable patients to enhance recovery without compromising oncologic effectiveness.